Focused-ultrasound developer InSightec has received clearance from the U.S. Food and Drug Administration to use its ExAblate 2000 incisionless surgery system for uterine fibroids with 3-tesla MRI scanners from GE Healthcare of Chalfont St. Giles, U.K.
ExAblate 2000 combines MRI with focused ultrasound waves to noninvasively destroy tumors. The system was previously approved in 2004 for use with 1.5-tesla magnets.
The Haifa, Israel-based company has begun clinical trials to study the technology's use in many oncology-based indications, including breast, bone, liver, and brain tumors.
By AuntMinnie.com staff writers
March 1, 2007
Related Reading
InSightec raises $15 million, August 10, 2006
InSightec to bring Exablate to Australia, Taiwan, June 21, 2006
InSightec reports first North American MRgFUS patient, May 31, 2006
Image guidance evolves into imaging therapy, May 12, 2006
Rapid interleaved technique speeds MRgFUS fibroid treatment, May 2, 2006
Copyright © 2007 AuntMinnie.com
